GlassScriptPhysician profile
Thomas J Curfman
NPI 1184621641
$1,240.95
in general payments reported to CMS, 2019-2025
23 companies · $96.34 in 2025
The $96.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $120 · 2021: $37.04 · 2022: $28.70 · 2023: $166 · 2024: $227 · 2025: $96.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.35 | 2020-2025 | Botox |
| Medtronic USA, INC. | $112.06 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $106.48 | 2019-2020 | |
| Nevro Corp. | $97.63 | 2023 | Senza |
| Pfizer INC. | $84.12 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $69.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $56.31 | 2019 | |
| Allergan, INC. | $55.25 | 2019-2020 | |
| Greenwich Biosciences, INC. | $30.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.64 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $26.71 | 2019 | |
| Ucb, INC. | $24.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.51 | 2024 | Andexxa |
| Ge Healthcare | $21.91 | 2019 | |
| Neurocrine Biosciences, INC. | $21.63 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $20.46 | 2019 | |
| Kyowa Kirin, INC. | $19.98 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.72 | 2019 | |
| Emd Serono, INC. | $14.69 | 2019 | |
| Eisai INC. | $14.16 | 2019 | |
| Lilly USA, LLC | $12.61 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Curfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.